Display options
Cite
Abdulrazaq M, Hamdan F, Al-Tameemi W. Electrophysiologic and clinico-pathologic characteristics of statin-induced muscle injury. Iran J Basic Med Sci. 2015;18(8):737-44
Abdulrazaq, M., Hamdan, F., & Al-Tameemi, W. (2015). Electrophysiologic and clinico-pathologic characteristics of statin-induced muscle injury. Iranian journal of basic medical sciences, 18(8), 737-44.
Abdulrazaq, Mohammed, et al. "Electrophysiologic and clinico-pathologic characteristics of statin-induced muscle injury." Iranian journal of basic medical sciences vol. 18,8 (2015): 737-44.
Abdulrazaq M, Hamdan F, Al-Tameemi W. Electrophysiologic and clinico-pathologic characteristics of statin-induced muscle injury. Iran J Basic Med Sci. 2015 Aug;18(8):737-44. PMID: 26557961; PMCID: PMC4633455.
Copy Download .nbib Format: NLM
Share it on

Iran J Basic Med Sci. 2015 Aug;18(8):737-44.

Electrophysiologic and clinico-pathologic characteristics of statin-induced muscle injury.

Iranian journal of basic medical sciences

Mohammed Abdulrazaq, Farqad Hamdan, Waseem Al-Tameemi

Affiliations

  1. Department of Physiology, College of Medicine, Al-Nahrain University, Baghdad, Iraq.
  2. Department of Medicine, College of Medicine, Al-Nahrain University, Baghdad, Iraq.

PMID: 26557961 PMCID: PMC4633455

Abstract

OBJECTIVES: In this study, we aimed at evaluation of electrophysiological and histopathalogical characteristics of statin-induced muscle injury as well as clinical features of patients who develop this condition in terms of frequency and pattern of evolution.

MATERIALS AND METHODS: Forty patients (age 39-74 years) including 25 subjects with type 2 diabetes mellitus, 9 with cardiovascular diseases and 6 with hyperlipidemia, who were receiving atrovastatin 40 mg/day for variable period, were studied. Thirty three healthy subjects (age 31-74 years) served as control group. Creatine phosphokinease level, thyroid function, motor unit potential parameters and muscle fiber conduction velocity of biceps brachii and tibialis anterior muscles were measured.

RESULTS: Creatine phosphokinase level was elevated in statin users, particularly in those with diabetes mellitus. Less than 50% of statin users experienced symptoms related to muscle injury. Muscle fiber conduction velocity of the biceps brachii muscle was significantly reduced. Statin users with diabetes mellitus showed significant changes in electrophysiological parameters as compared to those with cardiovascular diseases and hyperlipidemia. Muscle biopsies showed muscle fiber variation in size, fibrosis and mild inflammatory cell infiltration. Immunohistochemical evaluation of muscle biopsies showed positive expression of Bcl-2 and one patient showed positive P53 immunohistochemical expression with elevated level of creatine phosphokinase.

CONCLUSION: Atorvastatin increased average creatine kinase, statins produce mild muscle injury even in asymptomatic subjects. Diabetic statin users were more prone to develop muscle injury than others. Muscle fiber conduction velocity evaluation is recommended as a simple and reliable test to diagnose statin-induced myopathy instead of invasive muscle biopsy.

Keywords: EMG; Histopathology; Immune histochemistry; MFCV; Muscle injury; Statin

References

  1. Neurology. 1983 Nov;33(11):1453-9 - PubMed
  2. J Physiol. 1987 Oct;391:561-71 - PubMed
  3. Clin Pharmacokinet. 2012 Sep 1;51(9):591-606 - PubMed
  4. Curr Opin Rheumatol. 2010 Nov;22(6):644-50 - PubMed
  5. Expert Opin Drug Saf. 2011 May;10(3):373-87 - PubMed
  6. Intern Med J. 2002 Sep-Oct;32(9-10):486-90 - PubMed
  7. J Neurol Neurosurg Psychiatry. 2009 Aug;80(8):832-8 - PubMed
  8. Pharmacol Rep. 2011;63(4):859-66 - PubMed
  9. Cardiovasc Drugs Ther. 2005 Dec;19(6):403-14 - PubMed
  10. Am J Cardiol. 2006 Apr 17;97(8A):89C-94C - PubMed
  11. Mayo Clin Proc. 2002 Oct;77(10):1085-92 - PubMed
  12. Circulation. 2006 Dec 19;114(25):2788-97 - PubMed
  13. J Pharmacol Exp Ther. 2005 Sep;314(3):1032-41 - PubMed
  14. J Am Coll Cardiol. 2012 Dec 11;60(23):2384-90 - PubMed
  15. CMAJ. 2008 Feb 26;178(5):576-84 - PubMed
  16. Curr Rheumatol Rep. 2010 Jun;12(3):213-20 - PubMed
  17. Muscle Nerve. 2003 Feb;27(2):142-56 - PubMed
  18. J Appl Physiol (1985). 2006 Jun;100(6):1837-41 - PubMed
  19. Circulation. 2013 Jan 1;127(1):96-103 - PubMed
  20. Curr Neurol Neurosci Rep. 2008 Jan;8(1):66-72 - PubMed
  21. Am J Cardiol. 2006 Apr 17;97(8A):52C-60C - PubMed
  22. Curr Opin Rheumatol. 2007 Jan;19(1):67-73 - PubMed
  23. Arch Phys Med Rehabil. 2005 Mar;86(3 Suppl 1):S18-27 - PubMed
  24. Ann Pharmacother. 2002 Dec;36(12):1957-60 - PubMed
  25. Nat Rev Rheumatol. 2012 Aug;8(8):448-57 - PubMed
  26. Phys Med Rehabil Clin N Am. 2013 Feb;24(1):193-207 - PubMed
  27. Cancer Res. 2004 Sep 1;64(17):6233-9 - PubMed
  28. Arch Intern Med. 2005 Dec 12-26;165(22):2671-6 - PubMed
  29. CMAJ. 2009 Jul 7;181(1-2):E11-8 - PubMed
  30. J Clin Endocrinol Metab. 2010 Apr;95(4):1663-71 - PubMed
  31. Carcinogenesis. 2005 May;26(5):883-91 - PubMed
  32. Am J Cardiol. 2014 May 15;113(10):1765-71 - PubMed
  33. Neurol Clin. 2000 Aug;18(3):695-718 - PubMed
  34. J Am Coll Cardiol. 2007 Jun 12;49(23):2231-7 - PubMed
  35. Ann Intern Med. 2009 Jun 16;150(12):858-68 - PubMed
  36. J Pharm Pharmacol. 2005 Nov;57(11):1475-84 - PubMed
  37. Arq Neuropsiquiatr. 2004 Jun;62(2A):257-61 - PubMed
  38. Neurology. 2008 Oct 7;71(15):e34-7 - PubMed
  39. Reumatol Clin. 2012 Jul-Aug;8(4):195-200 - PubMed
  40. J Cardiovasc Pharmacol. 2002 Aug;40(2):163-71 - PubMed
  41. J Am Med Dir Assoc. 2001 May-Jun;2(3):110-4 - PubMed
  42. Mayo Clin Proc. 2015 Jan;90(1):24-34 - PubMed
  43. Muscle Nerve. 2010 Feb;41(2):185-90 - PubMed
  44. Ann Intern Med. 2002 Oct 1;137(7):581-5 - PubMed
  45. Drug Saf. 2010 Mar 1;33(3):171-87 - PubMed

Publication Types